Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 6/20 | 0.43 |
| ▸ | CCNC | P24863 | 5/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802107 | 0.91 | CDK8 (0.43) | CDK8CCNCUSP7BRD4CYP11B1 | |
| SCHEMBL17814084 | 0.88 | CDK8 (0.44) | CDK8CCNCUSP7TRPA1AR | |
| SCHEMBL17814136 | 0.82 | BRD4 (0.36) | USP7CREBBPBRD4CYP11B1CYP11B2 | |
| SCHEMBL19348298 | 0.81 | KDM1A (0.35) | USP7ARCYP11B1CYP11B2KDM1A | |
| SCHEMBL21105092 | 0.81 | CDK8 (0.39) | CDK8CCNCUSP7TRPA1AR | |
| SCHEMBL17814146 | 0.80 | CYP11B1 (0.49) | CDK8CCNCTRPA1ARCREBBP | |
| SCHEMBL17814131 | 0.79 | CYP11B2 (0.49) | CYP11B1CYP11B2 | |
| SCHEMBL17814124 | 0.79 | CCNC (0.45) | CDK8CCNCBRD4CYP11B1CYP11B2 | |
| SCHEMBL19348309 | 0.79 | CYP11B1 (0.37) | FAAHCYP11B1CYP11B2KDM1A | |
| SCHEMBL17802102 | 0.78 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | CDK8 2437/4885CCNC 2192/4885USP7 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.